{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:40:23Z","timestamp":1790091623177,"version":"4.0.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Extramedullary multiple myeloma (EMM) is an aggressive sub-entity of multiple myeloma (MM). Despite an excellent improvement in survival for most patients with MM over recent decades, the overall survival (OS) of patients with EMM was usually not longer than 3 years. Standard treatment for patients with EMM has not been established, and their management is particularly challenging. We presented a heavily pretreated young patient with relapsed EMM and refractoriness to a proteasome inhibitor (PI; bortezomib), a next-generation PI (ixazomib), immunomodulatory drugs (IMiDs; lenalidomide), autologous hematopoietic stem cell transplantation (ASCT), and monoclonal antibody (directed against CD38: daratumumab) and indicated that myeloablative haploidentical hematopoietic stem cell transplantation (haploidentical-HSCT) as a salvage treatment of relapse after a chimeric antigen receptor (CAR)-T cell therapy that targeted B-cell maturation antigen (BCMA) (NCT04650724) is feasible. Taken together of the contemporary literature, the promising results on the effect of anti-BCMA CAR-T cell therapy and allogeneic HSCT might present a proof-of-principle for patients with EMM, and therefore, patients with the disease need to be included in future studies.<\/jats:p>","DOI":"10.3389\/fmed.2021.649824","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T14:05:04Z","timestamp":1620396304000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Successful Treatment of Relapsed\/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature"],"prefix":"10.3389","volume":"8","author":[{"given":"Ying","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3109\/10428194.2012.740562","article-title":"Extramedullary multiple myeloma","volume":"54","author":"Weinstock","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","article-title":"How i treat extramedullary myeloma","volume":"127","author":"Touzeau","year":"2016","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2013.094409","article-title":"Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse","volume":"99","author":"Pour","year":"2014","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00277-016-2847-z","article-title":"The possible role of burden of therapy on the risk of myeloma extramedullary spread","volume":"96","author":"Mangiacavalli","year":"2017","journal-title":"Ann Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/bmt.2017.165","article-title":"Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome","volume":"52","author":"Kumar","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/ejh.13046","article-title":"Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis","volume":"100","author":"Pick","year":"2018","journal-title":"Eur J Haematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bjh.13799","article-title":"Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study","volume":"172","author":"Muchtar","year":"2016","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1002\/ajh.25428","article-title":"Chimeric antigen receptor T cell immunotherapy for multiple myeloma: a review of current data and potential clinical applications","volume":"94","author":"Susanibar Adaniya","year":"2019","journal-title":"Am J Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3324\/haematol.2019.219295","article-title":"A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome","volume":"105","author":"Beksac","year":"2020","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3324\/haematol.2017.178434","article-title":"Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT","volume":"103","author":"Gagelmann","year":"2018","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.bbmt.2019.07.004","article-title":"Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of the European Society for blood and marrow transplantation","volume":"25","author":"Gagelmann","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ejh.13217","article-title":"Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed\/refractory multiple myeloma","volume":"102","author":"Jimenez-Segura","year":"2019","journal-title":"Eur J Haematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/bjh.12881","article-title":"Long-term survival after allogeneic stem cell transplantation for advanced stage multiple myeloma","volume":"166","author":"Vekemans","year":"2014","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3324\/haematol.2018.200881","article-title":"Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life","volume":"104","author":"Greil","year":"2019","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1097\/CM9.0000000000000341","article-title":"Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma","volume":"132","author":"Chen","year":"2019","journal-title":"Chin Med J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbmt.2018.09.018","article-title":"Outcomes of haploidentical transplantation in patients with relapsed multiple myeloma: An EBMT\/CIBMTR Report","volume":"25","author":"Sahebi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbmt.2016.09.002","article-title":"Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse","volume":"23","author":"Kenderian","year":"2017","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.649824\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T14:05:07Z","timestamp":1620396307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.649824\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":29,"alternative-id":["10.3389\/fmed.2021.649824"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.649824","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"article-number":"649824"}}